Compounds > propacetamol
Page last updated: 2024-09-23

propacetamol

Description

propacetamol: prodrug for acetaminophen; structure given in UD; RN given refers to HCl; RN for parent cpd not available 5/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68865
CHEMBL ID1851805
CHEBI ID135089
SCHEMBL ID26155
MeSH IDM0175922

Synonyms (33)

Synonym
propacetamolum [latin]
n,n-diethylglycine, ester with 4'-hydroxyacetanilide
propacetamol [inn]
einecs 266-390-1
propacetamol
propacetamol (inn)
D07294
66532-85-2
CHEBI:135089
(4-acetamidophenyl) 2-(diethylamino)acetate
propacetamol [inn:ban]
propacetamolum
5chw4jmr82 ,
unii-5chw4jmr82
CHEMBL1851805
FT-0630766
AKOS015890722
propacetamol [mi]
propacetamol [who-dd]
SCHEMBL26155
cas-66532-85-2
tox21_113811
NCGC00253689-01
dtxsid3057800 ,
dtxcid7031589
glycine, n,n-diethyl-, 4-(acetylamino)phenyl ester
DB09288
4-acetamidophenyl 2-(diethylamino)acetate
BCP13498
Q907888
MS-23737
CS-0374746
HY-145453

Research Excerpts

Overview

ExcerptReference
"Propacetamol is a prodrug form of paracetamol (APAP) licensed for human use as a pain reliever in postoperative care. "( Gajda, A; Gbylik-Sikorska, M; Giorgi, M; Kim, TW; Lisowski, A; Pietruk, K; Poapolathep, A; Sartini, I; Łebkowska-Wieruszewska, B, 2022)
"Propacetamol is an APAP prodrug, which is clinically bioequivalent to APAP."( Ko, JL; Lai, YY; Liou, GG; Tsai, MS; Tsou, HK; Wang, SH; Wang, YH, 2018)
"Propacetamol (PPCM) is a prodrug of paracetamol (PCM), which was generated to increase water solubility of PCM for intravenous delivery. "( Eberhardt, E; Eberhardt, M; Leffler, A; Schillers, F, 2016)
"Propacetamol was found to be a major suspected drug of pharmacologically associated hypotension in Korea. "( Ban, GY; Jeong, CG; Kim, SH; Lee, HY; Lee, JH; Lee, YH; Park, SH; Ye, YM, 2017)
"Propacetamol is an injectable pro-drug of paracetamol (acetaminophen) with analgesic and antipyretic activities, especially used in the post-operative period. "( Hiesse-Provost, O; Hynes, D; McCarroll, M, 2006)
"Propacetamol is an acetaminophen prodrug that was available in Europe as an IV formu lation for the treatment of pain and fever for some time. "( Chesney, R; Jones, J; Rodarte, A; Walson, PD, 2006)

Actions

ExcerptReference
"Propacetamol did not enhance analgesia, nor did it decrease cumulative opioid consumption or reduce adverse effects in a dose of 2 g given every sixth hour for 3 days after surgery."( Hakala, T; Hendolin, H; Hynynen, M; Kokki, H; Lahtinen, P, 2002)

Drug Classes (1)

ClassDescription
alpha-amino acid esterThe amino acid ester derivative obtained the formal condensation of an alpha-amino acid with an alcohol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency37.57800.006038.004119,952.5996AID1159521
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency2.98490.001022.650876.6163AID1224838
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (120)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.67)18.7374
1990's36 (30.00)18.2507
2000's50 (41.67)29.6817
2010's20 (16.67)24.3611
2020's12 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials64 (51.61%)5.53%
Reviews5 (4.03%)6.00%
Case Studies5 (4.03%)4.05%
Observational1 (0.81%)0.25%
Other49 (39.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT02116257]108 participants (Actual)Interventional2013-11-30Completed
[NCT02577068]84 participants (Actual)Interventional2015-11-15Completed
Perioperative Regular Usage of Propacetamol to Reduce Post Cesarean Section Uterine Contraction Pain and Opioid Consumption[NCT03878082]100 participants (Actual)Interventional2019-08-12Completed
The Effect of Dexamethasone Versus Local Infiltration Technique on Postoperative Nausea and Vomiting After Tonsillectomy in Children: A Randomized Double-blind Clinical Trial[NCT02355678]129 participants (Actual)Interventional2015-01-31Completed
[NCT01833728]16 participants (Actual)Interventional2013-04-30Completed
Comparison of the Effect of Propacetamol, Ibuprofen or Their Combination on Postoperative Pain and Quality of Recovery After Laparoscopic Hernia Repair in Children[NCT03352362]159 participants (Actual)Interventional2017-12-15Completed
[NCT02515188]98 participants (Actual)Interventional2015-08-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
acetaminophen[no description available]medium11562acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
morphine[no description available]medium2319morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
parecoxib[no description available]medium54isoxazoles;
N-sulfonylcarboxamide		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
isoxazoles[no description available]medium54isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
ibuprofen[no description available]medium22monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
glycine[no description available]medium10alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
acetylcysteine[no description available]medium30acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
kaempferol[no description available]medium107-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
dexibuprofen[no description available]medium11ibuprofennon-narcotic analgesic;
non-steroidal anti-inflammatory drug
galangin[no description available]medium107-hydroxyflavonol;
trihydroxyflavone		antimicrobial agent;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
plant metabolite
fentanyl[no description available]medium33anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
tramadol[no description available]medium752-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanoladrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
metabolite;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor
acetic acid[no description available]medium10monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
dinoprostone[no description available]medium10prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
uric acid[no description available]medium10uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
aspirin[no description available]medium10benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
malondialdehyde[no description available]medium10dialdehydebiomarker
oxycodone[no description available]medium22organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
dipyrone[no description available]medium54organic sodium saltanti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug
trimeperidine[no description available]medium10
ketamine[no description available]medium21cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
methadone[no description available]medium11benzenes;
diarylmethane;
ketone;
tertiary amino compound
diclofenac[no description available]medium75amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
pirinitramide[no description available]medium33nitrile
meperidine[no description available]medium21ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
betamethasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
piperidines[no description available]medium33
nitrous oxide[no description available]medium11gas molecular entity;
nitrogen oxide		analgesic;
bacterial metabolite;
food packaging gas;
food propellant;
general anaesthetic;
greenhouse gas;
inhalation anaesthetic;
NMDA receptor antagonist;
raising agent;
refrigerant;
vasodilator agent
isoflurane[no description available]medium22organofluorine compoundinhalation anaesthetic
desflurane[no description available]medium11organofluorine compoundinhalation anaesthetic
remifentanil[no description available]medium30alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
remifentanil[no description available]medium33alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
ketoprofen[no description available]medium77benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
acetaminophen sulfate ester[no description available]medium11acetamides;
aryl sulfate		drug metabolite
acetaminophen glucuronide[no description available]medium21beta-D-glucosiduronic aciddrug metabolite
ketorolac[no description available]medium64amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
dextromethorphan[no description available]medium106-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthreneantitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic
n-demethyltramadol[no description available]medium10methoxybenzenes
o-demethyltramadol[no description available]medium10
dexmedetomidine[no description available]medium11medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
midazolam[no description available]medium11imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
nalbuphine[no description available]medium43organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
buprenorphine[no description available]medium32morphinane alkaloiddelta-opioid receptor antagonist;
kappa-opioid receptor antagonist;
mu-opioid receptor agonist;
opioid analgesic
diethylamine[no description available]medium10secondary aliphatic amine
clonidine[no description available]medium10clonidine;
imidazoline
sufentanil[no description available]medium10anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
lidocaine[no description available]medium10benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
bupivacaine[no description available]medium20aromatic amide;
piperidinecarboxamide;
tertiary amino compound
propofol[no description available]medium22phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
tolmetin[no description available]medium21aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
mobiflex[no description available]medium21heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
piroxicam[no description available]medium21benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
nefopam[no description available]medium11benzoxazocine;
tertiary amino compound
glucuronic acid[no description available]medium10D-glucuronic acidalgal metabolite
niflumic acid[no description available]medium10aromatic carboxylic acid;
pyridines
alaproclate[no description available]low00alpha-amino acid ester
camylofine[no description available]low00alpha-amino acid ester
ochratoxin c[no description available]low00alpha-amino acid ester;
isochromanes;
phenylalanine derivative		Aspergillus metabolite;
mycotoxin;
Penicillium metabolite
ng-nitroarginine methyl ester[no description available]low00alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
leucine methyl ester[no description available]low00alpha-amino acid ester;
L-leucine derivative;
methyl ester
methionine ethyl ester[no description available]low00alpha-amino acid ester;
L-methionine derivative		potassium channel blocker
diethyl aminomalonate[no description available]low00alpha-amino acid ester
arginine methyl ester[no description available]low00alpha-amino acid ester
n-acetylphenylalanine beta-naphthyl ester[no description available]low00alpha-amino acid ester;
phenylalanine derivative
perindopril[no description available]low00alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
thiamphenicol glycinate[no description available]low00alpha-amino acid ester
Cromoglicate lisetil[no description available]low00alpha-amino acid ester
2-[benzenesulfonyl(2-pyridinyl)amino]acetic acid methyl ester[no description available]low00alpha-amino acid ester
2-(2-oxo-3H-1,4-benzoxazin-4-yl)acetic acid [2-(3-bromo-4-methoxyphenyl)-2-oxoethyl] ester[no description available]low00alpha-amino acid ester
2-[[2-methyl-5-(3-methyl-4-oxo-1-phthalazinyl)phenyl]sulfonylamino]acetic acid ethyl ester[no description available]low00alpha-amino acid ester
phenylalanine methyl ester[no description available]low00alpha-amino acid ester;
L-phenylalanine derivative
2-(benzenesulfonamido)acetic acid [2-(4-nitrophenyl)-2-oxoethyl] ester[no description available]low00alpha-amino acid ester
2-[(4-methylphenyl)sulfonylamino]acetic acid [2-(5-bromo-2-thiophenyl)-2-oxoethyl] ester[no description available]low00alpha-amino acid ester
2-(1-benzimidazolyl)acetic acid [2-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester[no description available]low00alpha-amino acid ester
2-(2-methyl-1-benzimidazolyl)acetic acid [2-(2-methyl-1H-indol-3-yl)-2-oxoethyl] ester[no description available]low00alpha-amino acid ester
2-(2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)acetic acid (7-bromo-4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl ester[no description available]low00alpha-amino acid ester
alpha-acetyllysine methyl ester[no description available]low00acetamides;
alpha-amino acid ester;
L-lysine derivative;
methyl ester;
primary amino compound
mecysteine hydrochloride[no description available]low00alpha-amino acid ester
2-[[1-(4-chlorophenyl)-2,5-dioxo-3-pyrrolidinyl]-methylamino]acetic acid methyl ester[no description available]low00alpha-amino acid ester
4-(4-bromophenyl)-2-(3,5-dimethyl-1-pyrazolyl)-4-oxobutanoic acid methyl ester[no description available]low00alpha-amino acid ester
2-[(4-methylphenyl)sulfonylamino]acetic acid (2-oxo-3-oxolanyl) ester[no description available]low00alpha-amino acid ester
biricodar[no description available]low00alpha-amino acid ester
tryptophyl adenylate[no description available]low00adenosine 5'-phosphate;
alpha-amino acid ester;
L-tryptophan derivative;
purine ribonucleoside 5'-monophosphate		Mycoplasma genitalium metabolite
2-[8-[[bis(phenylmethyl)amino]methyl]-3-methyl-2,6-dioxo-7-purinyl]acetic acid ethyl ester[no description available]low00alpha-amino acid ester
2-(3-phenyl-1-indazolyl)acetic acid methyl ester[no description available]low00alpha-amino acid ester
2-[3-[3-(2-furanylmethylamino)-3-oxopropyl]-2,4-dioxo-1-thieno[3,2-d]pyrimidinyl]acetic acid (phenylmethyl) ester[no description available]low00alpha-amino acid ester
2-(7-methyl-4-oxo-3-furo[3,4]pyrrolo[3,5-c][1,2,4]triazinyl)acetic acid methyl ester[no description available]low00alpha-amino acid ester
2-[2-[(5-chloro-2-thiophenyl)-oxomethyl]imino-6-fluoro-1,3-benzothiazol-3-yl]acetic acid methyl ester[no description available]low00alpha-amino acid ester
2-[8-bromo-7-[(2-chlorophenyl)methyl]-3-methyl-2,6-dioxo-1-purinyl]acetic acid methyl ester[no description available]low00alpha-amino acid ester
2-[[(3-methoxyanilino)-oxomethyl]-[(3-methyl-2-thiophenyl)methyl]amino]acetic acid ethyl ester[no description available]low00alpha-amino acid ester
2-[8-[(2,6-dimethyl-4-morpholinyl)methyl]-1,3-dimethyl-2,6-dioxo-7-purinyl]acetic acid ethyl ester[no description available]low00alpha-amino acid ester
2-[2-[(3-chloro-1-benzothiophen-2-yl)-oxomethyl]imino-6-sulfamoyl-1,3-benzothiazol-3-yl]acetic acid ethyl ester[no description available]low00alpha-amino acid ester
2-[(2,6-dichlorophenyl)sulfonylamino]-3-methylbutanoic acid [2-(1H-indol-3-yl)-2-oxoethyl] ester[no description available]low00alpha-amino acid ester
2-[(4-acetamidophenyl)sulfonylamino]acetic acid [7-(ethoxycarbonylamino)-2-oxo-1-benzopyran-4-yl]methyl ester[no description available]low00alpha-amino acid ester
2-(2-chloro-1-oxoethyl)-3,4-dihydro-1H-isoquinoline-3-carboxylic acid methyl ester[no description available]low00alpha-amino acid ester
2-[8-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1,3-dimethyl-2,6-dioxo-7-purinyl]acetic acid methyl ester[no description available]low00alpha-amino acid ester
maytansine[no description available]low00alpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound		antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator
2-[6-[(5-chloro-2-methoxyphenyl)sulfamoyl]-2-oxo-1,3-benzoxazol-3-yl]acetic acid ethyl ester[no description available]low00alpha-amino acid ester
cinepazet[no description available]low00alpha-amino acid ester
s-farnesylcysteine alpha-carboxyl methyl ester[no description available]low00alpha-amino acid ester;
L-cysteine derivative
antazirine[no description available]low00alpha-amino acid ester
2-[3-(3,4-dimethoxyphenyl)-2,4-dioxo-1-quinazolinyl]acetic acid (phenylmethyl) ester[no description available]low00alpha-amino acid ester
2-[4-ethoxy-2-[2-furanyl(oxo)methyl]imino-1,3-benzothiazol-3-yl]acetic acid methyl ester[no description available]low00alpha-amino acid ester
(2S)-2-(1,3-dioxo-3a,4,5,6,7,7a-hexahydroisoindol-2-yl)propanoic acid (4-oxo-1,2,3-benzotriazin-3-yl)methyl ester[no description available]low00alpha-amino acid ester
2-[[3-[(2-ethoxy-2-oxoethyl)thio]-5-oxo-2H-1,2,4-triazin-6-yl]amino]acetic acid butyl ester[no description available]low00alpha-amino acid ester
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease0low10
2019 Novel Coronavirus Infection0low10
2019-nCoV Disease0low10
2019-nCoV Infection0low10
Abdominal Migraine0medium11
Ache0medium74
Acute Confusional Migraine0medium11
Acute Disease0medium32
Acute Liver Injury, Drug-Induced0low10
Acute Lung Injury0low10
Acute Pain0low10
Acute Post-operative Pain0medium5741
Acute Postoperative Pain0medium5741
Allergic Contact Dermatitis0low30
Anemia, Hemolytic0low10
Anemia, Hemolytic, Acquired0low10
Anemia, Microangiopathic0low10
Anoxemia0medium11
Anoxia0medium11
Anxiety0low10
Aqueductal Stenosis0low10
Arm Injuries0medium11
Atrial Fibrillation0medium21
Auricular Fibrillation0medium21
Benign Neoplasms0medium11
Benign Supratentorial Neoplasms0medium11
Birth Weight0low10
Blood Loss, Postoperative0medium11
Blood Poisoning0low10
Blood Pressure, High0medium11
Blood Pressure, Low0medium51
Bloodstream Infection0low10
Body Weight0medium21
Bradyarrhythmia0medium11
Bradyarrhythmias0medium11
Bradycardia0medium11
Breast Cancer0medium22
Breast Carcinoma0medium22
Breast Neoplasms0medium22
Breast Tumors0medium22
Burns0low10
Cancer0medium11
Cancer of Breast0medium22
Cancer of Larynx0low10
Cancer of Liver0medium11
Cancer of the Breast0medium22
Cancer of the Larynx0low10
Cancer of the Liver0medium11
Cancer, Hepatocellular0medium11
Cancer, Supratentorial0medium11
Canine Diseases0low10
Carcinoma, Epidermoid0low10
Carcinoma, Hepatocellular0medium11
Carcinoma, Planocellular0low10
Carcinoma, Squamous0low10
Carcinoma, Squamous Cell0low10
Cerebral Ventriculomegaly0low10
Cervical Migraine Syndrome0medium11
Chemical and Drug Induced Liver Injury0low10
Chemically-Induced Liver Toxicity0low10
Chronic Post-operative Pain0medium5741
Chronic Post-surgical Pain0medium5741
Chronic Postoperative Pain0medium5741
Chronic Postsurgical Pain0medium5741
Cirrhosis, Liver0medium11
Communicating Hydrocephalus0low10
Complication, Intraoperative0low10
Complication, Peroperative0low10
Congenital Hydrocephalus0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Coronary Disease0low10
Coronary Heart Disease0low10
Coronavirus Disease 20190low10
Coronavirus Disease-190low10
COVID-190low10
COVID-19 Pandemic0low10
COVID-19 Pandemics0low10
COVID-19 Virus Disease0low10
COVID-19 Virus Infection0low10
COVID190low10
Craniofacial Abnormalities0medium11
Critical Illness0medium32
Critically Ill0medium32
Deficiency of Glucose-6-Phosphate Dehydrogenase0low10
Deficiency, Glucosephosphate Dehydrogenase0low10
Deficiency, GPD0low10
Deficiency, Oxygen0medium11
Dermatitis, Allergic Contact0low30
Dermatitis, Allergic Eczematous0low30
Dermatitis, Contact, Allergic0low30
Dermatitis, Eczematous0low30
Dermatitis, Occupational0low70
Dermatosis, Industrial0low70
Disc, Herniated0medium11
Disease Models, Animal0low20
Disk Prolapse0medium11
Disk, Herniated0medium11
Dog Diseases0low10
Drug Overdose0low10
Drug-Induced Acute Liver Injury0low10
Drug-Induced Liver Disease0low10
Drug-Induced Liver Injury0low10
Eczema0low30
Emesis0medium22
Emesis, Postoperative0medium33
Exanthem0medium11
Exanthema0medium11
Extravascular Hemolysis0low10
Eyelid Diseases0low10
Facial Dermatoses0low10
Facial Dermatosis0low10
Familial Atrial Fibrillation0medium21
Favre-Racouchot Syndrome0low10
Female Genital Diseases0medium11
Fetal Cerebral Ventriculomegaly0low10
Fever, Zika0low10
Fibrosis, Liver0medium11
G6PD Deficiency0low10
Gastroduodenal Ulcer0low10
Genital Diseases, Female0medium11
Glucose 6 Phosphate Dehydrogenase Deficiency0low10
Glucose-6-Phosphate Dehydrogenase Deficiency0low10
Glucosephosphate Dehydrogenase Deficiencies0low10
Glucosephosphate Dehydrogenase Deficiency0low10
GPD Deficiency0low10
Grippe0low10
Gynecologic Diseases0medium11
Haemolysis0low10
Haemolytic Anaemia0low10
Hand Dermatoses0low30
Hand Dermatosis0low30
Headache, Migraine0medium11
Heart Valve Diseases0low10
Heart Valvular Disease0low10
Hemicrania Migraine0medium11
Hemolysis0low10
Hemolytic Anemia0low10
Hemolytic Anemia Due to G6PD Deficiency0low10
Hemolytic Anemia, Acquired0low10
Hemorrhage, Postoperative0medium11
Hemorrhages, Postoperative0medium11
Hepatic Cancer0medium11
Hepatic Cirrhosis0medium11
Hepatic Neoplasms0medium11
Hepatitis, Drug-Induced0low10
Hepatitis, Toxic0low10
Hepatocellular Cancer0medium11
Hepatocellular Carcinoma0medium11
Hepatoma0medium11
Hernia, Inguinal0medium33
Herniated Disc0medium11
Herniated Disk0medium11
Human Flu0low10
Human Influenza0low10
Human Mammary Carcinoma0medium22
Hydrocephalus0low10
Hydrocephalus Ex-Vacuo0low10
Hydrocephaly0low10
Hyperparathyroidism0medium21
Hypertension0medium11
Hypotension0medium51
Hypotension, Vascular0medium51
Hypoxemia0medium11
Hypoxia0medium11
Idiopathic Inflammatory Myopathies0low10
Idiopathic Inflammatory Myopathy0low10
Idiopathic Inflammatory Myositis0low10
Industrial Dermatosis0low70
Infant, Premature, Diseases0low30
Infection0medium11
Infection and Infestation0medium11
Infections0medium11
Infections and Infestations0medium11
Infections, Respiratory0medium11
Infections, Respiratory Tract0medium11
Infections, Upper Respiratory0medium11
Infections, Upper Respiratory Tract0medium11
Infectious Myositis0low10
Inflammation0low10
Inflammatory Muscle Diseases0low10
Inflammatory Myopathies, Idiopathic0low10
Inflammatory Myopathy0low10
Inflammatory Myopathy, Idiopathic0low10
Inflammatory Response Syndrome, Systemic0medium11
Influenza0low10
Influenza in Humans0low10
Influenza, Human0low10
Inguinal Hernia0medium33
Inguinal Hernia, Direct0medium33
Inguinal Hernia, Indirect0medium33
Injuries, Arm0medium11
Injuries, Leg0medium11
Injuries, Surgical0low10
Innate Inflammatory Response0low10
Intervertebral Disc Displacement0medium11
Intervertebral Disk Displacement0medium11
Intraoperative Complications0low10
Intravascular Hemolysis0low10
Kidney Calculi0medium11
Kidney Stones0medium11
Laryngeal Cancer0low10
Laryngeal Neoplasms0low10
Larynx Cancer0low10
Larynx Neoplasms0low10
Leg Injuries0medium11
Liver Cancer0medium11
Liver Cancer, Adult0medium11
Liver Cell Carcinoma0medium11
Liver Cell Carcinoma, Adult0medium11
Liver Cirrhosis0medium11
Liver Fibrosis0medium11
Liver Injury, Drug-Induced0low10
Liver Injury, Drug-Induced, Acute0low10
Liver Neoplasms0medium11
Low Blood Pressure0medium51
Lung Injury, Acute0low10
Malignancy0medium11
Malignant Neoplasm of Breast0medium22
Malignant Neoplasms0medium11
Malignant Supratentorial Neoplasms0medium11
Malignant Tumor of Breast0medium22
Mammary Cancer0medium22
Mammary Carcinoma, Human0medium22
Mammary Neoplasm, Human0medium22
Mammary Neoplasms, Human0medium22
Marginal Ulcer0low10
Microangiopathic Hemolytic Anemia0low10
Migraine0medium11
Migraine Disorders0medium11
Migraine Headache0medium11
Migraine Variant0medium11
Muscle Diseases, Inflammatory0low10
Myopathies, Idiopathic Inflammatory0low10
Myopathy, Inflammatory0low10
Myositis0low10
Myositis, Focal0low10
Myositis, Infectious0low10
Myositis, Proliferative0low10
Nausea and Vomiting, Postoperative0medium33
Nausea, Postoperative0medium33
Neoplasia0medium11
Neoplasm0medium11
Neoplasms0medium11
Neoplasms, Benign0medium11
Neoplasms, Breast0medium22
Neoplasms, Hepatic0medium11
Neoplasms, Laryngeal0low10
Neoplasms, Liver0medium11
Neoplasms, Supratentorial0medium11
Nephrolith0medium11
Nodular Elastoidosis0low10
Nodular Elastosis0low10
Obstructive Hydrocephalus0low10
Occupational Dermatitis0low70
Oxygen Deficiency0medium11
Pain, Burning0medium74
Pain, Crushing0medium74
Pain, Migratory0medium74
Pain, Post-operative0medium5741
Pain, Postoperative0medium5741
Pain, Radiating0medium74
Pain, Splitting0medium74
Paroxysmal Atrial Fibrillation0medium21
Peptic Ulcer0low10
Peroperative Complications0low10
Persistent Atrial Fibrillation0medium21
Persistent Postsurgical Pain0medium5741
Poisoning, Blood0low10
PONV0medium33
Post-operative Pain0medium5741
Post-operative Pain, Acute0medium5741
Post-operative Pain, Chronic0medium5741
Post-surgical Pain0medium5741
Post-Traumatic Hydrocephalus0low10
Postoperative Emesis0medium33
Postoperative Hemorrhage0medium11
Postoperative Hemorrhages0medium11
Postoperative Nausea0medium33
Postoperative Nausea and Vomiting0medium33
Postoperative Pain0medium5741
Postoperative Pain, Acute0medium5741
Postoperative Pain, Chronic0medium5741
Postoperative Vomiting0medium33
Postsurgical Pain0medium5741
Pregnancy0medium11
Primary Supratentorial Neoplasms0medium11
Prolapsed Disc0medium11
Prolapsed Disk0medium11
Pyaemia0low10
Pyemia0low10
Pyohemia0low10
Pyrexia0medium127
Rash0medium11
Renal Calculi0medium11
Renal Calculus0medium11
Respiratory Infections0medium11
Respiratory Tract Infections0medium11
Retinopathy of Prematurity0medium11
Retrolental Fibroplasia0medium11
Rhabdomyolysis0low10
SARS Coronavirus 2 Infection0low10
SARS-CoV-2 Infection0low10
Sepsis0low10
Sepsis Syndrome0medium11
Septicemia0low10
Severe Sepsis0low10
Sick Headache0medium11
Skin Rash0medium11
Slipped Disc0medium11
Slipped Disk0medium11
Squamous Cell Carcinoma0low10
Status Migrainosus0medium11
Suffering, Physical0medium74
Supratentorial Neoplasms0medium11
Supratentorial Neoplasms, Benign0medium11
Supratentorial Neoplasms, Malignant0medium11
Supratentorial Neoplasms, Primary0medium11
Supratentorial Tumors0medium11
Surgical Injuries0low10
Systemic Inflammatory Response Syndrome0medium11
Tachyarrhythmia0medium11
Tachycardia0medium11
Teeth, Impacted0medium11
Tooth, Impacted0medium11
Toxic Hepatitis0low10
Tumors0medium11
Tumors, Breast0medium22
Upper Respiratory Infections0medium11
Upper Respiratory Tract Infection0medium11
Upper Respiratory Tract Infections0medium11
Urinary Tract Diseases0medium11
Urinary Tract Infections0low10
Urologic Diseases0medium11
Urological Diseases0medium11
Valvular Heart Diseases0low10
Vascular Hypotension0medium51
Vomiting0medium22
Vomiting, Postoperative0medium33
Wounds, Penetrating0medium11
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (7)

ArticleYear
The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial.
BMC pediatrics, 06-23, Volume: 18, Issue: 1		2018
Galangin Prevents Acute Hepatorenal Toxicity in Novel Propacetamol-Induced Acetaminophen-Overdosed Mice.
Journal of medicinal food, Volume: 18, Issue: 11		2015
Comparison of the efficacy and safety of different doses of propacetamol for postoperative pain control after breast surgery.
Pain management nursing : official journal of the American Society of Pain Management Nurses, Volume: 16, Issue: 3		2015
Clinical analgesic efficacy and side effects of dexmedetomidine in the early postoperative period after arthroscopic knee surgery.
Journal of clinical anesthesia, Volume: 19, Issue: 8		2007
Antipyretic efficacy and safety of a single intravenous administration of 15 mg/kg paracetamol versus 30 mg/kg propacetamol in children with acute fever due to infection.
International journal of clinical pharmacology and therapeutics, Volume: 45, Issue: 4		2007
Adjunctive analgesia with intravenous propacetamol does not reduce morphine-related adverse effects.
British journal of anaesthesia, Volume: 90, Issue: 3		2003
Analgesic efficacy and safety of nefopam vs. propacetamol following hepatic resection.
Anaesthesia, Volume: 56, Issue: 6		2001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (7)

ArticleYear
Propacetamol in dogs: First description of its pharmacokinetics after intravenous and oral administration.
Research in veterinary science, Volume: 144		2022
Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery.
Paediatric anaesthesia, Volume: 18, Issue: 7		2008
Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates.
European journal of clinical pharmacology, Volume: 60, Issue: 3		2004
Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age.
Archives of disease in childhood. Fetal and neonatal edition, Volume: 89, Issue: 1		2004
Rapid liquid chromatographic assay for the determination of acetaminophen in plasma after propacetamol administration: application to pharmacokinetic studies.
Journal of pharmaceutical and biomedical analysis, Volume: 20, Issue: 1-2		1999
Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate.
Developmental pharmacology and therapeutics, Volume: 20, Issue: 3-4		1993
Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use.
Fundamental & clinical pharmacology, Volume: 6, Issue: 6		1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (2)

ArticleYear
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use.
Fundamental & clinical pharmacology, Volume: 6, Issue: 6		1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (13)

ArticleYear
Galangin Prevents Acute Hepatorenal Toxicity in Novel Propacetamol-Induced Acetaminophen-Overdosed Mice.
Journal of medicinal food, Volume: 18, Issue: 11		2015
Effect of intravenous propacetamol on blood pressure in febrile critically ill patients.
Pharmacotherapy, Volume: 28, Issue: 10		2008
Clinical analgesic efficacy and side effects of dexmedetomidine in the early postoperative period after arthroscopic knee surgery.
Journal of clinical anesthesia, Volume: 19, Issue: 8		2007
Analgesic efficacy of parenteral paracetamol (propacetamol) and diclofenac in post-operative orthopaedic pain.
Acta anaesthesiologica Scandinavica, Volume: 50, Issue: 3		2006
Propacetamol and diclofenac alone and in combination for analgesia after elective tonsillectomy.
Acta anaesthesiologica Scandinavica, Volume: 48, Issue: 9		2004
Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates.
European journal of clinical pharmacology, Volume: 60, Issue: 3		2004
Bioequivalence study comparing a new paracetamol solution for injection and propacetamol after single intravenous infusion in healthy subjects.
International journal of clinical pharmacology and therapeutics, Volume: 42, Issue: 1		2004
Assessing analgesia in single and repeated administrations of propacetamol for postoperative pain: comparison with morphine after dental surgery.
Anesthesia and analgesia, Volume: 98, Issue: 1		2004
Symptomatic intravenous antipyretic therapy: efficacy of metamizol, diclofenac, and propacetamol.
Journal of pain and symptom management, Volume: 24, Issue: 6		2002
[Metamizol versus propacetamol: comparative study of the hemodynamic and antipyretic effects in critically ill patients].
Revista espanola de anestesiologia y reanimacion, Volume: 49, Issue: 8		2002
Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement.
Anesthesia and analgesia, Volume: 92, Issue: 6		2001
Isobolographic analysis of interactions between intravenous morphine, propacetamol, and diclofenac in carrageenin-injected rats.
Anesthesiology, Volume: 87, Issue: 2		1997
Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate.
Developmental pharmacology and therapeutics, Volume: 20, Issue: 3-4		1993
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (2)

ArticleYear
A double-blinded evaluation of propacetamol versus ketorolac in combination with patient-controlled analgesia morphine: analgesic efficacy and tolerability after gynecologic surgery.
Anesthesia and analgesia, Volume: 88, Issue: 3		1999
[Comparison of the analgesic efficacy of nalbuphine and its combination with propacetamol during the immediate postoperative period in gynecologic-obstetric surgery].
Annales francaises d'anesthesie et de reanimation, Volume: 13, Issue: 2		1994
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]